(Reuters) - Three pharmacy chains, including Walgreens Boots Alliance WBA.O, have filed a lawsuit against drugmakers Bausch Health Inc BHC.TO, Assertio Therapeutics ASRT.O and Lupin Ltd LUPN.NS, seeking damages for overcharging for Bausch's diabetes drug Glumetza.
The lawsuit, filed on Monday, alleges that Assertio and Lupin struck a deal with units of Bausch to delay the entry of their generic versions of Glumetza and allowed the companies to “maintain a monopoly” in the sale of the branded drug and its generic copies.
Bausch, Assertio and Lupin did not immediately respond to Reuters’ request for comment.
Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.